series-a
Stage
4
Investors
About
Therini Bio is a clinical-stage biotechnology company developing fibrin-targeting immunotherapies to block vascular-mediated inflammation and neuronal damage in neurological and retinal diseases. Its pipeline includes THN391, a candidate being tested in Phase 1b trials for diabetic macular edema and Alzheimer's disease.
Explore Therini Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.